Innoviva Inc (INVA)
Innoviva, Inc. is a NASDAQ-listed common stock company in the healthcare sector with a focus on pharmaceuticals. The company operates as a biopharmaceutical business in the United States and internationally and is tied to a royalty portfolio that includes RELVAR/BREO ELLIPTA and ANORO ELLIPTA. It also markets several infectious disease and critical care products, including GIAPREZA, XACDURO, XERAVA, ZEVTERA, and NUZOLVENCE. In addition, Innoviva is developing bacteriophages for potential use across infectious and other serious diseases. The company maintains a strategic partnership with Sarissa Capital Management LP and a LABA collaboration agreement with Glaxo Group Limited. Formerly known as Theravance, Inc., the company adopted the Innoviva name in 2016 and was incorporated in 1996. Its headquarters are in Burlingame, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-INVA
|
$24.82
|
29.0% Upside
|
Undervalued
|
$35
|
81.9% Upside
|
Bargain
|
Great
|
0.0%
|
March 3, 2027
|
7.1x
|
1.2x
|
3.1x
|
1.365 B
|
574.8 M
|
14.4%
|
3.7
|
94.3%
|
